CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the 18th Annual Needham Healthcare Conference on Wednesday, April 10 at 10:40 A.M. ET in New York, NY.
A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. Replays of the webcasts will be archived for 90 days following the conferences.
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted cancer vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on individual patient immune responses. Genocea’s lead neoantigen vaccine candidate, GEN-009, is currently being evaluated in a Phase 1/2a clinical trial. Genocea is also developing GEN-011, an investigational adoptive T cell therapy. For more information, please visit www.genocea.com.